Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists-Reference-Cited by-同舟云学术

Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists

Published:2011-12 Issue:3 Volume:80 Page:369-379
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Ederhy Stephane,Izzedine Hassan,Massard Christophe,Dufaitre Ghislaine,Spano Jean Philippe,Milano Gerard,Meuleman Catherine,Besse Benjamin,Boccara Franck,Kahyat David,Cohen Ariel,Soria Jean Charles

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference80 articles.

1. Tyrosine kinases as targets for cancer therapy;Krause;N Engl J Med,2005

2. VEGF-targeted therapy: mechanisms of anti-tumour activity;Ellis;Nat Rev Cancer,2008

3. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition;Force;Nat Rev Cancer,2007

4. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib;Chu;Lancet,2007

5. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate;Kerkelä;Nat Med,2006

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The cardio and renoprotective role of ginseng against epinephrine-induced myocardial infarction in rats: Involvement of angiotensin II type 1 receptor/protein kinase C;Toxicology Reports;2021

2. Possibilities of supportive therapy in patients with blood system tumors and malignant neoplasms;Oncohematology;2020-10-16

3. Childhood cancer survivors: The integral role of the cardiologist and cardiovascular imaging;American Heart Journal;2020-08

4. Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol;Therapeutic Advances in Medical Oncology;2020-01

5. Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition;JACC: CardioOncology;2019-09